New Zealand's former cricketer Bob Blair dies at 94

Wellington, June 24 -- Former New Zealand fast bowler Bob Blair, whose courage in the aftermath of one of the country's worst rail disasters became one of cricket's most enduring stories, has died on ... Read More

Aliganj fire reveals gaps in electrical safety reforms post-Levana tragedy

India, June 24 -- LUCKNOW Nearly four years after the devastating fire at Hotel Levana Suites in Lucknow prompted the UP government to order sweeping reforms in electrical safety oversight, another ma... Read More

CAP Plc appoints executive director, company secretary

Nigeria, June 24 -- Chemical and Allied Products Plc (CAP Plc), a subsidiary of UAC of Nigeria Plc, has appointed Jethro Iruobe as Executive Director, effective 25 June. In his capacity as an executi... Read More

Twin train mishaps disrupt Ctg's rail links for over three hours

Cumilla, June 24 -- Rail communications of Chattogram with the rest of the country remained suspended for more than three hours on Wednesday after the locomotive of a train broke down near Hasanpur St... Read More

Singapore Clinical Trial: A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety and tolerability of ARD001 in healthy adult subjects and a Phase 2 open-label, multiple-dose study in adult subjects with hemophilia A

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating ... Read More

Singapore Clinical Trial: A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Pla... Read More

Singapore Clinical Trial: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solut... Read More

Singapore Clinical Trial: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib M... Read More

Singapore Clinical Trial: A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembr... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Eval... Read More

• ««
• «
• 12867
• 12868
• 12869
• 12870
• 12871
• 12872
• 12873
• 12874
• 12875
• 12876
• »
• »»